Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Multivariate analysis of EFS according to standard parameters and the combined B-Cell/IL8-metagene in TNBC

From: A clinically relevant gene signature in triple negative and basal-like breast cancer

   Finding cohort A* Validation cohort C*
Variable   No. of patients Hazard ratio 95% CI P-value No. of patients§ Hazard ratio 95% CI P-value
Lymph node status LNN vs N1 210 vs 27 0.59 0.31 to 1.12 0.10 43 vs 29 0.40 0.17 to 0.99 0.046
Age > 50 vs ≤ 50 113 vs 124 0.75 0.48 to 1.17 0.21 48 vs 24 1.68 0.65 to 4.38 0.29
Tumor size ≤ 2 cm vs > 2 cm 71 vs 166 0.73 0.44 to 1.21 0.22 11 vs 61 0.99 0.28 to 3.42 0.98
Histological grading G3 vs G1 and 2 166 vs 71 1.11 0.68 to 1.81 0.68 59 vs 13 0.53 0.22 to 1.29 0.16
B-Cell/IL8-Signature Good vs Poor|| 78 vs 159 0.38 0.22 to 0.67 0.001 29 vs 43 0.21 0.07 to 0.62 0.005
  1. * Results from multivariate Cox analysis of event free survival in the TNBC finding cohort A and validation cohort C are presented.
  2. † information on all parameters was available for 237 of the 297 TNBC samples with follow up data from the finding cohort A.
  3. ‡ Significant P-values are given in bold
  4. § information on all parameters was available for 72 of the 76 TNBC samples with follow up data from the validation cohort C.
  5. || "Good" refers to high B-Cell metagene together with low IL8 metagene expression compared to all the remaining samples referred as "Poor".